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Abstract
Background: ID2 is a member of a subclass of transcription regulators belonging to the general bHLH (basic-helix-loop-
helix) family of transcription factors. In normal cells, ID2 is responsible for regulating the balance between proliferation and
differentiation. More recent studies have demonstrated that ID2 is involved in tumor progression in several cancer types
such as prostate or breast.
Methodology/Principal Findings: In this work, we investigated, for the first time, the relationship between the expression
of ID2 in non-small cell lung cancer (NSCLC) patients and the clinicopathological features and prognosis of these patients.
Immunohistochemistry was performed on tissue microarrays, which included 62 NSCLC tumors. In malignant tissues, ID2
expression has been detected in both the nuclear and cytoplasmic compartments, but we have demonstrated that only
nuclear expression of ID2 is inversely correlated with the differentiation grade of the tumor (p=0.007). Interestingly, among
patients with poorly differentiated tumors, high nuclear expression of ID2 was an independent and unfavorable prognostic
factor for survival (p=0.036).
Conclusions: These results suggest that ID2 could be involved in tumor dedifferentiation processes of NSCLC, and could be
used as prognostic marker for patients with poorly differentiated tumors.
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Introduction
ID2 (Inhibitor of DNA binding 2) belongs to a subclass of
proteins, the ID family, found within the large bHLH (basic-helix-
loop-helix) group of transcription factors. Interestingly, as they do
not possess the basic domain, ID proteins do not directly bind to
DNA and, instead, act as dominant negative antagonists of class A
bHLH transcription factors. Among the known targets of ID
proteins are the E protein and members of the Ets family [1]. ID
proteins are involved in tissue development [2,3], and have been
described as inhibitors of differentiation in numerous cell types
including myeloid cells [4], B lymphocytes [5], and muscle cells
[6]. ID2 expression is generally low in normal tissues, and is up-
regulated in tumors. High levels of expression have been observed
in malignancies such as neuroblastoma [7,8], colorectal adeno-
carcinoma [9], Ewing sarcoma [10], prostate cancer [11], and
pancreatic cancer [12]. Altogether, these results suggest that ID2
may play an important role in tumor initiation and progression.
To date, there is only a single study evaluating the role of ID2 in
lung cancer, specifically in small cell lung cancer (SCLC) [13].
Lung cancer is a leading cause of deaths from cancer worldwide.
The most abundant histological type that affects about 80% of
patients is non-small cell lung cancer (NSCLC), as opposed to
small cell lung cancer. The overall 5-year survival rate of NSCLC
patients is about 15% [14]. Once a diagnosis has been established,
treatment options are typically based on stage and histology [15],
although this stratification scheme does not consistently reflect the
biology of tumor. As a result, over 50% of patients with early-stage
lung cancer will eventually die, while others at a more advanced
stage will survive [14,16], underlying the need for additional
prognostic markers to better predict the outcome of the disease
[17].
In this paper, we have evaluated the expression of ID2 by
immunohistochemistry on NSCLC tissue microarrays containing
62 tumors. We then further investigated the relationships between
ID2 expression and clinicopathologic parameters, in order to
assess its possible role as a prognostic marker for NSCLC.
Results
ID2 Expression in Normal Lung and in NSCLC Tissues
Immunostaining for ID2 was performed on a tumor microarray
(TMA) containing 62 NSCLC samples from human patients. The
clinical and histological features of patients are described in
Table 1. In non-cancerous lung tissue, weak to moderate ID2
expression was detected in bronchial epithelial cells in both the
cytoplasm and nuclei. In addition, weak ID2 staining was observed
in the cytoplasm of endothelial cells (Figure 1A–D).
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highly diverse both in terms of intensity and localization (Figure 1).
Out of 62 NSCLC patients, a large proportion (98%, 61/62)
expressed ID2 protein almost exclusively in tumor cells (median of
global staining score=3; range 0 to 18). Nuclear immunoreactivity
was positive in 33 (53.3%) of the NSCLC samples (median of
nuclear staining score=1; range 0 to 11), and cytoplasmic ID2 was
detected in 57 (92%) out of 62 tumors (median of cytoplasmic
staining score=2; range 0 to 8). Many poorly differentiated
tumors exhibited strong ID2 staining in the nuclei in conjunction
with weak or moderate cytoplasmic staining (Figure 1E–J). In
contrast, ID2 was not expressed in the nuclei of partially or well-
differentiated tumors, while weak to moderate expression was
observed in the cytoplasm (Figure 1K–P).
Association of ID2 Expression with Clinicopathological
Parameters
The median of the staining score for either nuclear, cytoplasmic,
or global expression of ID2, as described above, was used as a cut
off to classify patients in two groups: ‘‘low’’ (i.e., low ID2
expression) and ‘‘high’’ (i.e., high ID2 expression). Multiple
component analysis (MCA) was performed on data collected from
the 62 patients and the graphical representation is presented in
Figure 2A. In brief, variable neighborhoods on the graph are
potentially associated together. MCA showed that low nuclear
expression of ID2 was associated with well-differentiated tumors
and lymph node involvement. In contrast, high expression of ID2
in the nucleus was seen more frequently in tumors that were
poorly differentiated and had advanced local invasion (T3–T4
status). In association with MCA, DEMOD analysis was
performed and demonstrated a significant association between
nuclear expression of ID2 and histological differentiation of
NSCLC (Figure 2B). Our results showed 15 out of 17 (88%) well-
differentiated tumors exhibited low expression levels of ID2. In
addition, poorly differentiated tumors had strong nuclear expres-
sion of ID2 (p=0.007) in 12 out of 19 (63%) cases. However, no
significant relationship was found between ID2 expression and
lymph node involvement or T status, possibly due to the uneven
distribution of T status between groups (52 and 10 patients in T1–
T2 and T3–T4, respectively). Cytoplasmic expression of ID2 was
not associated with the differentiation grade of the NSCLC, but
was surprisingly linked to the histological type of tumors. Tumor
expression of ID2 was high in 22 out of 33 (67%) cases of
adenocarcinoma compared to 5 out of 19 (26%) cases of squamous
cell carcinoma (p=0.016) (Figure 2B).
Univariate and Multivariate Survival Analysis
To determine whether immunostaining of ID2 had a prognostic
value, we examined the association between global, nuclear, and
cytoplasmic expression of ID2 with the overall survival of patients.
First, we analyzed conventional clinicopathological parameters.
We observed a significant impact of tumor stage (p=0.0001) and
tumor size (p=0.014) on patient overall survival (Figures 3A–C),
whereas nodal status (N0 vs. N+) was of borderline significance
(p=0.06). Histological differentiation was not a prognostic marker
in our cohort of NSCLC patients (p=0.48; data not shown).
Similarly, we did not observe a significant difference in the overall
survival between patients with high expression levels of ID2 and
those exhibiting low expression levels of ID2 (Figure 3D–E).
However, after stratification of the data according to histological
differentiation (Figure 3G–I), poorly differentiated NSCLC
patients with high nuclear expression showed a shorter overall
survival than patients with low ID2 nuclear expression (median of
survival=24 vs. 41 months, respectively; p=0.036; Figure 3G). In
addition, multivariate analysis using Cox’s regression model
demonstrated that nuclear ID2 expression in patients with poorly
differentiated tumors was an independent prognostic factor of
overall survival (p=0.034; RR=13.7; IC 95%=1.2–161;
Table 2). No prognostic value of ID2 nuclear expression was
observed in moderate or well-differentiated tumors (data not
shown).
Discussion
The role of ID2 has been studied in several types of cancer (i.e.,
prostate, breast, colorectal, neuroblastoma, and very recently small
cell lung cancer), but to date, nothing is known about the
expression of ID2 in non-small cell lung cancer, which affects 80%
of patients with lung malignancies. Here, we focused on the
expression of ID2 in NSCLC and its relationship with the
clinicopathological parameters and prognosis of the disease.
Expression of ID2 was evaluated in 62 NSCLC tumors by
immunohistochemistry using tissue microarrays. While the
majority of the patients analyzed in this study expressed ID2,
the patient group was very heterogeneous with regard to both
expression level and intracellular localization. However, we have
Table 1. Clinical and histological features of patients with
NSCLC.
n( % )
All 62 100
Sex
Female 8 13
Male 54 87
Smoking status
Non smokers 5 8
Smokers 57 92
Histological type
Adenocarcinoma 33 53
Squamous cell carcinoma 19 31
Other type 10 16
Differentiation/Grade
Well 17 27
Moderately 26 42
Poorly 19 31
T status
T1–T2 52 84
T3–T4 10 16
N status
N0 38 62
N+ 23 38
M status
M0 52 84
M+ 10 16
Stage
I–II 36 58
III–IV 26 42
Other types: include large cell carcinoma, carcinoma, and bronchioalveolar
carcinoma.
doi:10.1371/journal.pone.0004158.t001
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correlated with poor differentiation of the tumor. This observation
is well in agreement with known properties of ID2, since the
protein has been characterized as an inhibitor of differentiation in
numerous tissues, including the epidermis and muscle [18,19].
Thus, ID2 inhibits muscular differentiation by direct interaction
with MyoD, a bHLH transcription factor required for myoblastic
differentiation [20]. Moreover, in prostate carcinoma, strong ID2
expression was associated with poorly differentiated grades of
tumor, suggesting that ID2 could also be involved in regulation of
tumor dedifferentiation [11,21]. Our data showed that a high
nuclear expression level of ID2 was an independent and negative
prognostic marker of survival in patients with poorly differentiated
lung tumors. Thus, patients with tumors exhibiting high nuclear
expression of ID2 have 13.7-fold higher risk of death than patients
with low expression of ID2. The prognostic value of high ID2
expression has already been demonstrated in other cancer types
such as neuroblastoma and prostate cancer [7,11,21,22,23].
However, previous studies on breast cancer and SCLC have
reported that high cytoplasmic expression of ID2 was associated
with a good prognosis, whereas no correlation was found between
nuclear expression of ID2 and the survival of patients [13,22].
Kamalian et al. suggested that in SCLC increased expression of
ID2 in cytoplasm could be due to its export from nuclei and may
Figure 1. ID2 immunohistochemistry in normal bronchial epithelium (A–B) and in NSCLC (C–H). A–B: ID2 staining of epithelial and
endothelial cells in non-cancerous lung. C–F: Representative expression on TMA with strong ID2 staining in nucleus and with moderate (C, D) or weak
(E, F) cytoplasmic staining. C, D are poorly differentiated adenocarcinomas and E, F is a poorly differentiated large cell carcinoma. G–H: Tumor with
absence of nuclear staining with moderate (G, H) cytoplasmic expression of ID2. G, H are moderately differentiated squamous cell carcinomas.
doi:10.1371/journal.pone.0004158.g001
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PLoS ONE | www.plosone.org 3 January 2009 | Volume 4 | Issue 1 | e4158Figure 2. Graphic representation of multiple correspondence analysis (A) and DEMOD analysis results (B). A: Nuclear, cytoplasmic, and
global expression of ID2 within NSCLC tumors have been used as active variables and are represented by bold squares and circle. Clinicopathological
features (i.e., differentiation, histological type, genre, smoking status, stage, and TNM classification) have been used as illustrative variables and are
represented by open lozenge. All variables were placed according to the gravity center of all patients belonging to the represented category. Clinical
parameters potentially associated with ID2 expression are underlined and in italics. B: DEMOD analysis was performed to identify statistical
associations between ID2 expression and clinicopathological features. Only parameters identified with MCA have been presented in the table (i.e.,
histological type, T status, lymph node involvement status, and differentiation of tumor).
doi:10.1371/journal.pone.0004158.g002
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in agreement with our study, as we demonstrated a direct
relationship between nuclear expression of ID2 and the survival of
patients. However, differences regarding ID2 localization may
originate in part from differences between the two pathologies, but
also from differences in the specificity of the antibodies. Indeed, we
have used Zymed antibodies as recommended by Perk et al., who
warned against the use of poorly specific ID2 antibodies [24].
Altogether, our data suggest that both ID2 expression and
intracellular localization must be evaluated in order to determine
the prognosis for cancer patients, including those with lung cancer.
The intracellular localization of ID2 may play a major role in the
control of ID2 function and cell fate regulation. Kurooka et al.
determined that the nucleo-cytoplasmic shuttling of ID2 is an
active mechanism dependent on the CRM-1 protein, and is
inversely correlated to transcriptional repression via the E-box
sequence [25]. In addition, Lasorella and Iavarone demonstrated
that the interaction between ID2 and the actin-associated protein
enigma homolog (ENH) also controls the localization of ID2 [26].
Indeed, downregulation of ENH expression prevents relocalization
of ID2 into the cytoplasm in differentiated neuroblastoma cells.
This result allows us to speculate on the possible implication of
ENH or CRM-1 protein in the dedifferentiation mechanism of
NSCLC. Our results indicate that nuclear ID2 is likely to be a
Figure 3. Survival analysis. A–F: Kaplan—Meier curves established for all NSCLC patients (n=59) according to disease stage (A), nodal status (B), T
status (C), nuclear (D), cytoplasmic (E), and global expression of ID2 (F). G–I: Kaplan—Meier curves obtained for patients with poorly differentiated
tumors (n=18) according to nuclear (G), cytoplasmic (H), and global (I) expression of ID2. Curves were compared with log-rank test.
doi:10.1371/journal.pone.0004158.g003
Table 2. Mutivariate survival analysis after stratification
according to patients with poorly differentiated tumors.
Variables Relative Risk 95% CI p value
T status 6.7 1.1–39.1 0.035
N status 2.05 0.4–9.5 0.36
Nuclear expression of ID2 13.7 1.2–161 0.034
doi:10.1371/journal.pone.0004158.t002
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ID2 to the cytoplasm may explain the lack of prognostic value for
cytoplasmic ID2. However, the role of ID2 compartmentalization
in lung tumor progression, although potentially interesting, would
require further evaluation.
The mechanism by which ID2 promotes lung tumor progres-
sion is not clear yet. However, results obtained in other models
suggest that the action of ID2 could depend on the inhibition of
Rb tumor suppressor pathway [3,27]. In addition, it has been
demonstrated that ID2 also regulates angiogenesis and apoptosis
via transcriptional regulation of the VEGF and BCL2 genes,
respectively [28,29]. However, action of ID2 could also be tissue
specific: in breast cancer cell lines, high expression of ID2 reduced
growth potential and invasiveness, while up-regulation of ID2
increased proliferation and invasive potential in prostate tumor
cells [11,22,23].
Finally, although our results are preliminary, they suggest that
ID2 could be involved in the tumor dedifferentiation processes of
NSCLC, and could be used as prognosis marker for patients with
poorly differentiated tumors. Interestingly, in NSCLC, poorly
differentiated carcinomas are difficult to classify, and as such, the
identification of novel prognostic makers for this particular group
may help improve the therapeutic outcome of the patients.
Materials and Methods
Tumor samples
We have analyzed tissue samples collected in a prospective
group of 62 patients with NSCLC, who had undergone complete
surgical resection of the lung tumor as an initial treatment (i.e.,
without prior radiotherapy or chemotherapy) between January
2002 and August 2004 at the Thoracic Surgery Department of
Trousseau Hospital (Tours, France). Surgical specimens were fixed
in 10% formalin and paraffin embedded for routine histological
examination and immunohistochemistry. Histological types,
differentiation, TNM classification, and stage grouping (summa-
rized in Table I) were determined in accordance with the World
Health Organization (WHO) criteria for lung tumors [30].
Written consent was obtained from all of the patients included
in this study as recommended by French legislation.
Tissue Microarray Manufacturing and
Immunohistochemistry
For tissue microarray (TMA) manufacturing, representative
areas of the NSCLC samples were identified by a surgical
pathologist on hematoxylin-eosin (HE) stained slides. For each
tumor, three core biopsies 1 mm in diameter were then taken from
selected areas of donor blocks and arrayed into a recipient paraffin
block using a manual tissue arrayer (Beecher instruments, Sun
Prairie, USA). Sections (4 mm thick) of TMA blocks were cut and
immunohistochemistry was performed using a rabbit polyclonal
specific antibody raised against ID2 (ZMD.325, Invitrogen, Cergy
Pontoise, France). Briefly, the TMA section was deparaffinized,
rehydrated, and submitted to heat antigen retrieval in an
ethylenediamine tetra acetic acid buffer (MS-Unmasker, pH 7.8,
Diapath) for 20 min. ID2 antibody was applied at a 1/50 dilution.
Immunostaining was performed with the Lab Vision Autostainer
(Lab Vision, Fremont, USA) using a biotin-streptavidin-peroxidase
detection system with diaminobenzidine as a chromogen (Chem-
Mate
TM Detection kit, DakoCytomation). Slides were hematoxylin
counterstained. The TMA contained core samples of normal
bronchiolar mucosa and lung tissue. Specificity of ID2 antibody
was control by using purified ID2 protein as a negative control to
block binding of ID2 antibodies to tumor cells (Figure S1).
Two independent observers (J.R., C.B.) evaluated both the
localization and intensity of the ID2 staining. This evaluation was
blinded to the clinical data. Both nuclear and cytoplasmic staining
scores of tumor cells were established by multiplying the staining
intensity scaled from 0 to 3 (null=0, weak=1, moderate=2, and
strong=3) by the percentage of positive cells (0=,10%; 1=10–
25%; 2=26–50%; 3=51–75%; 4=.75%). Global expression of
ID2 in tumor cells was obtained by the addition of nuclear and
cytoplasmic staining scores.
Statistical Analysis
Multiple component analysis (MCA) was performed on data
collected from 62 patients using SPAD software. This method is a
descriptive multivariate analysis that allows for rapid identification
of statistical relationships between variables. Briefly, the different
categories, i.e., ID2 expression and clinicopathological features,
were positioned in multidimensional space. In order to observe
distances between points, they were projected on a plane of two
orthogonal factors, F1 and F2. These ‘first’ factors were chosen to
be the most representative of the global variance of the data.
Because the position of categories of active variables (nuclear,
cytoplasmic, and global expression of ID2) and the position of
observations (stage, lymph node status, tumor status, histological
types, grade of differentiation, genre, and smoking status) are
calculated in the same way, they can be placed on the same graph
(observations being replaced by gravity centers). DEMOD method
(SPAD software), similar to the chi-square test, was also used to
complement the MCA for analyzing the association between the
active variables (nuclear, cytoplasmic, and global expression of
ID2) and the illustrative variables (clinicopathological features).
Overall survival was calculated from the time of histology
diagnosis to the date of death due to any cause. The overall
survival rate was analyzed according to the Kaplan–Meier
method, and the differences in survival rates were assessed by
the log-rank test (Medcalc software version 7.3.0.1). Multivariate
analysis of prognostic factors was performed using Cox propor-
tional hazard model (Medcalc).
Supporting Information
Figure S1 Immunohistochemical analysis of paraffin-embedded
human NSCLC using rabbit polyclonal antibody against ID2.
IHC was performed with antibody alone (A and C) or after
neutralization of antibody by preincubation with 2 mg/mL of
purified ID2 protein (ID2 recombinant protein P01, Abnova,
Taiwan), overnight at 4uC, (B and D).
Found at: doi:10.1371/journal.pone.0004158.s001 (9.11 MB TIF)
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